Our Services
Medical Information
Helpful Resources
Published on: 9/12/2026
Stage 3 cirrhosis, also called bridging fibrosis, means extensive scar tissue now connects different areas of the liver, yet the organ still performs most of its work and symptoms may be mild, vague, or absent. Stage 4 is true cirrhosis, where scarring is widespread and permanent, blood flow through the liver is obstructed, and complications such as fluid buildup in the abdomen, variceal bleeding, jaundice, confusion, and liver failure become far more likely. The practical difference comes down to function and reversibility: stage 3 damage can sometimes be slowed or partially improved by treating the underlying cause, while stage 4 care centers on controlling complications and assessing transplant eligibility. Staging, symptoms, lab findings, and outlook vary considerably from person to person, so review the complete answer below before drawing conclusions about your own situation.
Because early liver scarring is easy to mistake for fatigue, stress, or digestive upset, and because catching it at stage 3 rather than stage 4 can meaningfully change your options, it is worth taking a few minutes for a free, instant, online symptom check to organize what you are experiencing and understand which next steps and questions to bring to a doctor.
Last reviewed for medical accuracy: 09/12/2026
Cirrhosis is the result of long-term damage to the liver. Healthy tissue is replaced by scar tissue, which impairs liver function. Doctors commonly classify cirrhosis into four stages. Stages 1 and 2 often have few or no symptoms. Stages 3 and 4 are more advanced and require close monitoring.
Key points:
In stage 3 cirrhosis, the liver’s ability to filter toxins, produce proteins, and regulate clotting factors is substantially reduced. Patients often develop complications like ascites (fluid buildup in the abdomen), varices (enlarged veins prone to bleeding), and hepatic encephalopathy (confusion from toxin buildup).
Factors affecting prognosis:
Life expectancy estimates (sourced from clinical studies and the Model for End‐Stage Liver Disease, or MELD score):
Stage 4 cirrhosis, also called end-stage liver disease, carries the highest risk of life-threatening complications:
Common complications include:
Life expectancy estimates:
| Feature | Stage 3 | Stage 4 |
|---|---|---|
| Scar tissue | Extensive, but some liver function remains | Widespread, minimal residual function |
| Common complications | Ascites, varices, mild encephalopathy | Severe bleeding, infections, renal failure |
| Symptom severity | Moderate | Severe |
| Life expectancy | 2–10 years (depending on factors) | 6 months–2 years without transplant |
| Treatment focus | Managing complications, slowing damage | Palliative care, transplant evaluation |
Stage 3 symptoms may include:
Stage 4 symptoms may include:
Whether you’re facing stage 3 or stage 4 cirrhosis, certain steps can help improve outcomes and quality of life:
Address the root cause
Control complications
Regular monitoring
Nutrition and lifestyle
Transplant evaluation
Living with advanced cirrhosis can be emotionally challenging. Consider:
If you’re experiencing any new or worsening symptoms, you might consider doing a free, online symptom check, using the doctor approved Ubie Symptom Checker to better understand what you’re feeling and determine next steps.
Always consult a healthcare professional if you notice:
Any of these could signal a life-threatening complication.
Understanding the difference between stage 3 and stage 4 cirrhosis helps you anticipate challenges and focus on treatments that can extend life expectancy and improve quality of life. While stage 3 offers more time for interventions, stage 4 underlines the urgency of transplant evaluation and palliative measures. Speak to a doctor about any concerning symptoms or treatment decisions—early and proactive care can make a significant difference.
(References)
* Narciso-Schiavon JL, Pereira JG, Silva TE, Bansho ETO, Morato EF, Pinheiro JT, Muraro-Wildner L, Bazzo ML, Dantas-Corrêa EB, Schiavon LL. Circulating levels of pentraxin-3 (PTX3) in patients with liver cirrhosis. Ann Hepatol. 2017 Sep-Oct;16(5):780-787. doi: 10.5604/01.3001.0010.2789. PMID: 28809733.
* Maimone S, Saffioti F, Oliva G, Di Benedetto A, Alibrandi A, Filomia R, Caccamo G, Saitta C, Cacciola I, Pitrone C, Squadrito G, Raimondo G. Erectile dysfunction in compensated liver cirrhosis. Dig Liver Dis. 2019 Jun;51(6):843-849. doi: 10.1016/j.dld.2018.10.015. Epub 2018 Oct 29. PMID: 30467076.
* Mihailovici AR, Donoiu I, Gheonea DI, Mirea O, Târtea GC, Buşe M, Calborean V, Obleagă C, Pădureanu V, Istrătoaie O. NT-proBNP and Echocardiographic Parameters in Liver Cirrhosis: Correlations with Disease Severity. Med Princ Pract. 2019;28(5):432-441. doi: 10.1159/000499930. Epub 2019 Apr 16. PMID: 30995644; PMCID: PMC6771067.
* Labenz C, Toenges G, Schattenberg JM, Nagel M, Huber Y, Marquardt JU, Labenz J, Galle PR, Wörns MA. Outcome Prediction of Covert Hepatic Encephalopathy in Liver Cirrhosis: Comparison of Four Testing Strategies. Clin Transl Gastroenterol. 2020 Jun;11(6):e00172. doi: 10.14309/ctg.0000000000000172. PMID: 32568474; PMCID: PMC7339190.
* Cheng CY, Kung CT, Wu KH, Chen FC, Cheng HH, Cheng FJ, Huang JB, Su CM. Liver cirrhosis affects serum lactate level measurement while assessing disease severity in patients with sepsis. Eur J Gastroenterol Hepatol. 2021 Sep 1;33(9):1201-1208. doi: 10.1097/MEG.0000000000001826. PMID: 32576767; PMCID: PMC8322043.
* Mo YH, Chen HL, Hsu WM, Chang CH, Peng SS. A noninvasive index to predict liver cirrhosis in biliary atresia. Pediatr Radiol. 2021 Feb;51(2):257-264. doi: 10.1007/s00247-020-04823-w. Epub 2020 Sep 22. PMID: 32964265.
* Hagström H, Lindfors A, Holmer M, Bengtsson B, Björkström K, Hegmar H, von Seth E. Etiologies and outcomes of cirrhosis in a large contemporary cohort. Scand J Gastroenterol. 2021 Jun;56(6):727-732. doi: 10.1080/00365521.2021.1912167. Epub 2021 Apr 19. PMID: 33872099.
* Giashuddin S, Alawad M. Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH). Methods Mol Biol. 2022;2455:1-18. doi: 10.1007/978-1-0716-2128-8_1. PMID: 35212981.
* Trifan A, Minea H, Rotaru A, Stanciu C, Stafie R, Stratina E, Zenovia S, Nastasa R, Singeap AM, Girleanu I, Muzica C, Huiban L, Cuciureanu T, Chiriac S, Sfarti C, Cojocariu C. Predictive Factors for the Prognosis of Alcoholic Liver Cirrhosis. Medicina (Kaunas). 2022 Dec 16;58(12). doi: 10.3390/medicina58121859. Epub 2022 Dec 16. PMID: 36557061; PMCID: PMC9786187.
* Noureddin M, Rinella ME, Chalasani NP, Neff GW, Lucas KJ, Rodriguez ME, Rudraraju M, Patil R, Behling C, Burch M, Chan DC, Tillman EJ, Zari A, de Temple B, Shringarpure R, Jain M, Rolph T, Cheng A, Yale K. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH. N Engl J Med. 2025 Jun 26;392(24):2413-2424. doi: 10.1056/NEJMoa2502242. Epub 2025 May 9. PMID: 40341827.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.